Infections in the Hematopoietic Cell Transplantation Setting: Improving Outcomes Through Interdisciplinary Care

Released On
February 24, 2020

Expires On
February 23, 2021

Media Type

Completion Time
90 minutes

Hospitalist, Infectious Disease, Medical Microbiology, Nephrology, Pathology, Pharmacy, Pulmonology, Radiology, Surgery


Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Postgraduate Institute for Medicine; ProCE; SIDPEC; and Terranova Medica LLC.

Supported by an independent educational grant from Merck & Co., Inc.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)
  • Healthcare Team — 1.5 Interprofessional Continuing Education credits

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is directed to infectious disease physicians, critical care physicians, hospitalists, surgeons, pathologists, hematologists/oncologists, pharmacists, and other healthcare providers responsible for the prevention and management of infections in the HCT setting.

Program Overview

Infections with bacterial, viral, and fungal pathogens remain significant drivers of mortality in HCT. Given the impact of profound immunosuppression on the risk for infection, infectious complications are a major concern in this population. Modifiable factors contributing to the performance gap include inadequate interdisciplinary care, entrenched treatment patterns, limitations of current guidelines in addressing strategies for the immunocompromised population, and competency gaps in integrating newer therapeutic options into the treatment paradigm, particularly pharmacologic optimization. This initiative is focused on addressing those performance/competency gaps.

Learning Objectives

Upon completing this activity, participants should be better able to:

  • Identify risk factors for recurrent Clostridioides difficile infection (CDI) in patients undergoing hematopoietic cell transplantation (HCT)
  • Provide patient-tailored therapy for CDI in patients undergoing HCT
  • Select appropriate therapy to prevent and manage cytomegalovirus (CMV) infection in patients undergoing HCT
  • Examine the interrelationship between CMV infection and fungal infection in patients undergoing HCT
  • Select appropriate therapy for hospital-acquired and ventilator-associated pneumonia (HABP/VABP) in patients undergoing HCT
  • Describe interdisciplinary team-based approaches to manage infections in the HCT setting


Carolyn Alonso, MD, FIDSA

Assistant Professor of Medicine, Harvard Medical School
Division of Infectious Diseases, Beth Israel Deaconess Medical Center
Director, Transplant and Immunocompromised Host Infectious Diseases Service
Boston, Massachusetts

Vasilios Athans, PharmD, BCPS, BCIDP

Infectious Diseases Clinical Pharmacy Specialist
Department of Pharmacy
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania

Dayna McManus, PharmD, BCPS, AQ-ID

Senior Clinical Pharmacy Specialist—Infectious Diseases
Residency Program Director
Yale New Haven Hospital
New Haven, Connecticut

Jennifer L. Saullo, MD, PharmD

Assistant Professor of Medicine
Department of Medicine
Duke University School of Medicine
Durham, North Carolina

Frank Tverdek, PharmD, BCPS, AQ-ID, CMQ

Clinical Pharmacy Manager, Clinical Pharmacy Programs
Clinical Pharmacy Specialist, Infectious Diseases
MD Anderson Cancer Center
Houston, Texas

Eduardo Yepez Guevara, MD

Assistant Professor
Department of Infectious Diseases
Infection Control and Employee Health
Division of Internal Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Accreditation Statement

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM); ProCE, Inc.; Terranova Medica, LLC; and the Society of Infectious Diseases Pharmacists Educational Center (SIDPEC™). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Disclosures of Conflicts of Interest

PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest or a commercial interest.

Carolyn Alonso, MD, FIDSA

  • FINANCIAL SUPPORT: Alnylam Pharmaceuticals (salary [spouse]); Moderna Therapeutics (stock sale [spouse])

Vasilios Athans, PharmD, BCPS, BCIDP

  • No conflicts to disclose.

Dayna McManus, PharmD, BCPS, AQ-ID

  • No conflicts to disclose.

Jennifer L. Saullo, MD, PharmD

  • No conflicts to disclose.

Frank Tverdek, PharmD, BCPS, AQ-ID, CMQ

  • No conflicts to disclose.

Eduardo Yepez Guevara, MD

  • No conflicts to disclose.

Planning Committee Disclosures:

The PIM, ProCE, and Terranova Medica, LLC planners and managers have nothing to disclose. Melissa Johnson, PharmD, MHS, AAHIVP, of the SIDPEC™, discloses the following: advisory board for Paratek; Astellas; Shionogi & Company, Ltd.; and Cidara Therapeutics; research support from Merck & Co., Inc. and Shionogi & Company, Ltd.; and royalties from UpToDate.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Instructions for Participation and Credit:

There are no fees for participating and receiving CME/CE credit for this activity. During the accreditation period, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

  1. Register and complete all the sections
  2. Complete all the online Posttest sections with a score of 75% or better
  3. Once you complete the Posttest, a link to the evaluation will be unlocked
  4. Upon completion of the evaluation, you will receive an immediate CME/CE Certificate to download and/or print for your files


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Privacy Policy

Terranova Medica, LLC; PIM; and ProCE are committed to protecting the privacy of those who choose to participate in activities on This information below describes our security policies for safeguarding personal information as well as the rationale for collection and use of personal information.

Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and use of personal information
Terranova Medica, LLC; PIM; and ProCE do not transfer, sell, or share personal information with outside parties. We will not disclose the information unless required in a legal proceeding

Contact Information

If you have any questions about this activity, please contact Tom Davis of Terranova Medica, LLC by telephone/fax (877-276-4523) or email (